RECORDATI : FINALIZES THE FIRST TRANCHE OF ITS ACQUISITION OF OPALIA PHARMA IN TUNISIA

Milan,  31 October 2013 - Recordati  announces the successful  conclusion of the
acquisition  of approximately 67% of the share  capital of Opalia Pharma S.A., a
Tunisian  pharmaceutical company with headquarters in Ariana, a suburb of Tunis.
This  first tranche consists  of the portion  of the share  capital held by non-
Tunisian  shareholders, one of which is The  Abraaj Group.  An amount of € 22.6
million were paid at the closing. The conclusion of the acquisition of a further
23% is expected to take place in the coming months.

Opalia   Pharma   was   established   in  1988, ranks  eighth  in  the  Tunisian
pharmaceutical market and is the third largest local pharmaceutical company. The
company  markets branded generic drugs with  leading products in dermatology and
in  the gastrointestinal and respiratory  therapeutic areas. Opalia manufactures
most of its products in a modern, cGMP certified production facility specialized
in  liquid  and  semi-solid  forms.  The  company  employs around 320 people and
generates annual sales of around TND 40 million (around € 18 million).


Recordati, established in 1926, is an international pharmaceutical group, listed
on  the  Italian  Stock  Exchange  (Reuters  RECI.MI,  Bloomberg REC IM, ISIN IT
0003828271), with  a  total  staff  of  over  3,300, dedicated  to the research,
development,  manufacturing and  marketing of  pharmaceuticals. Headquartered in
Milan,  Italy,  Recordati  has  operations  in  the  main European countries, in
Russia,  in other Central and  Eastern European countries, in  Turkey and in the
United   States   of   America.   A  field  force  of  more  than  1,700 medical
representatives  promotes  a  wide  range  of  innovative  pharmaceuticals, both
proprietary  and under  license, in  a number  of therapeutic  areas including a
specialized  business dedicated to treatments for  rare diseases. Recordati is a
partner  of choice for  new product licenses  for its territories.  Recordati is
committed  to  the  research  and  development  of  new drug entities within the
cardiovascular  and  urogenital  therapeutic  areas  and  of treatments for rare
diseases.   Consolidated revenue for 2012 was  € 828.3 million, operating income
was € 167.0 million and net income was € 118.5 million.

For further information:

Recordati website:  www.recordati.com

Investor       Relations                                                   Media
Relations
Marianne             Tatschke
Ketchum
(39)0248787393                                             Cristina   Risciotti,
(39)0262411919, cristina.risciotti@ketchum.com
e-mail:    inver@recordati.it                                             Marzia
Ongaretti,                                                       (39)0262411915,
marzia.ongaretti@ketchum.com


Statements contained in this release, other than historical facts, are "forward-
looking  statements"  (as  such  term  is  defined  in  the  Private  Securities
Litigation  Reform  Act  of  1995). These  statements  are  based  on  currently
available information, on current best estimates, and on assumptions believed to
be reasonable. This information, these estimates and assumptions may prove to be
incomplete  or erroneous, and  involve numerous risks  and uncertainties, beyond
the  Company's control. Hence,  actual results may  differ materially from those
expressed  or  implied  by  such  forward-looking  statements.  All mentions and
descriptions  of Recordati  products are  intended solely  as information on the
general  nature of the company's activities and are not intended to indicate the
advisability of administering any product in any particular instance.

RECORDATI FINALIZES THE FIRST TRANCHE OF ITS ACQUISITION OF OPALIA PHA: http://hugin.info/143644/R/1739671/583970.pdf

[HUG#1739671]

Rydex Inverse 2X S&P Select Se (NYSE:REC)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025